Placebo Tablet: BID

Phase 3

Otsuka

Placebo Tablet: BID is one of 17 therapeutic programs targeting Phenylketonuria. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[2][1]

Indication

PhenylketonuriaRecruiting

PhenylketonuriaPhase 3

Recruiting

Competition

Competitive Landscape

29 competitors in Phenylketonuria

#DrugCompanyPhaseTrials

Avelox

Bayer

Approved

—2

L-Carnitine

IIperboreal Pharma Srl

Approved

1 3

BMN 333

BioMarin Pharmaceutical

Phase 2

1 4

CEB-01

BioMarin Pharmaceutical

Phase 3

1 5

PTC923

PPTC Therapeutics

Phase 3

2 6

Kuvan

BioMarin Pharmaceutical

Preclinical

5 7

Placebo Tablet: BID

Otsuka

Phase 3

1 8

Immunosuppression

NNational Heart, Lung, and Blood Institute (NHLBI)

Phase 2

1 9

Kuvan

BioMarin Pharmaceutical

Preclinical

5 10

Tetrahydrobiopterin

OOrphanetics Pharma Entwicklungs GmbH

Phase 1

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2028

Phase 3Recruiting

Phenylketonuria

NCT06971731

Clinical

Trials by Indication[1]

Phenylketonuria1 trial

A Phase 3, Double-Blind, Randomized, Two-Period, Multicenter, Placebo-Controlled, Efficacy and Safety Study of JNT-517 for the Treatment of Participants With Phenylketonuria

Recruiting· Otsuka logo

Otsuka·Phase 3·NCT06971731·120 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Placebo Tablet: BID. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for Placebo Tablet: BID. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — Otsuka company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Phase 3[1]
Company: Otsuka

Placebo Tablet: BID

Status by Indication[2][1]

Competitive Landscape

Expected Milestones

Q2 2028

Trials by Indication[1]

Phenylketonuria1 trial

References

Drug Info

Quick Facts

Related News